Akebia Therapeutics, Inc. (AKBA) — 10-Q Filings
All 10-Q filings from Akebia Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Akebia's Cash Surges Amidst Auryxia Generic Threat
— Nov 10, 2025 Risk: high
Akebia Therapeutics, Inc. reported a significant increase in cash and cash equivalents to $166,444 thousand as of September 30, 2025, up from $51,870 thousand a -
Akebia's Auryxia Drives Strong Q2 Revenue Growth
— Aug 7, 2025 Risk: medium
Akebia Therapeutics, Inc. reported total revenue of $49.8 million for the three months ended June 30, 2025, a significant increase from $39.5 million in the sam -
Akebia Therapeutics Files Q1 2025 10-Q
— May 8, 2025 Risk: medium
Akebia Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial performance and operations. Key financ -
Akebia Therapeutics Q3 2024: Revenue Down, Net Loss Widens
— Nov 7, 2024 Risk: medium
Akebia Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2024. The company's revenue for the nine months ended Septemb -
Akebia Therapeutics Q2 2024 10-Q Filed
— Aug 8, 2024 Risk: medium
Akebia Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported revenue from product sales and license/collaboration agreemen -
Akebia Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk:
Akebia Therapeutics, Inc. (AKBA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Akebia Therapeutics, Inc. filed a 10-Q report for the period endin
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX